Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL291124 | 0.88 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNAHTTCA12CA1 | |
| SCHEMBL7440470 | 0.85 | MEN1 (0.56) | SMN1; SMN2LMNAHTTCA12CA1 | |
| SCHEMBL2192192 | 0.85 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNAHTTPLAUCA12 | |
| SCHEMBL13741500 | 0.84 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAHTTCA12CA1 | |
| SCHEMBL6044738 | 0.84 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNAHTTL3MBTL1NPC1 | |
| SCHEMBL18002248 | 0.83 | SMN1; SMN2 (0.58) | SMN1; SMN2LMNAHTTPLAUCA12 | |
| SCHEMBL1610723 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAHTTPLAUCA12 | |
| SCHEMBL6044415 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAHTTL3MBTL1NPC1 | |
| SCHEMBL15677565 | 0.82 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNAHTTCA12CA1 | |
| SCHEMBL21985416 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2LMNAHTTCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324176-B2 | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-12-04 | — | — | US | disclosed |
| US-20120165541-A1 | METHOD FOR THE PREPARATION OF W-AMINO- ALKANEAMIDES AND W-AMINO-ALKANETHIOAMIDES AS WELL AS INTERMEDIATES OF THIS METHOD | SANDOZ AG | 2012-06-28 | — | — | US | disclosed |
| EP-1548024-B1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-8158790-B2 | Cyclic amine compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-04-17 | — | — | US | disclosed |
| EP-2036896-B1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2012-03-14 | — | — | EP | disclosed |
| WO-2012010651-A2 | METHOD FOR THE PREPARATION OF OMEGA-AMINO-ALKANEAMIDES AND OMEGA-AMINO-ALKANETHIOAMIDES AS WELL AS INTERMEDIATES OF THIS METHOD | SANDOZ AG (CH) | 2012-01-26 | — | — | WO | disclosed |
| WO-2011012319-A1 | METHOD FOR THE PREPARATION OF W-AMINO-ALKANEAMIDES AND W-AMINO-ALKANETHIOAMIDES AS WELL AS INTERMEDIATES OF THIS METHOD | SANDOZ AG (CH) | 2011-02-03 | — | — | WO | disclosed |
| US-7635684-B2 | treatment of disease associated with hyperglycemia: diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity; e.g. -[(4-{3-[N-(Carbamoylmethyl)-N-(methanesulfonyl)amino]-propoxy}-2-methylphenyl)methyl]-3-( beta -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-12-22 | — | — | US | disclosed |
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090203633-A1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | KISSEI PHARMACEUTICAL CO., LTD (JP) | 2009-08-13 | — | — | US | disclosed |
| EP-2036896-A1 | CYCLIC AMINE COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-20050272669-A1 | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2005-12-08 | — | — | US | disclosed |
| EP-1548024-A1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2005-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203633-A1 | PYRAZOLE DERIVATIVES, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF, AND INTERMEDIATE FOR PRODUCTION THEREOF | UGGT1, GCKR, SLC5A1 | SMN1; SMN2 4382/4885LMNA 2896/4885HTT 2188/4885 |
| US-20050272669-A1 | Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof | UGGT1, GCKR, SLC5A1 | SMN1; SMN2 4382/4885LMNA 2896/4885HTT 2188/4885 |
| US-20090286807-A1 | CYCLIC AMINE COMPOUND | HRH3, HRH4, H1-0 | SMN1; SMN2 4464/4885LMNA 1720/4885HTT 635/4885 |
| US-20120165541-A1 | METHOD FOR THE PREPARATION OF W-AMINO- ALKANEAMIDES AND W-AMINO-ALKANETHIOAMIDES AS WELL AS INTERMEDIATES OF THIS METHOD | ABHD6, AADAT, LYPLA2 | SMN1; SMN2 3964/4885LMNA 1938/4885HTT 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.